Abstract
Background: In the UK, nearly 60% of VTE events are hospital acquired7. Thromboembolic events in COVID patients could be ranging from 20-30% 1,2,3 to as high as 40-70%4,5,6 in both ICUs and wards. Trust’s VTE prophylaxis guideline 733FM.5 and 66FM.3 state VTE assessment and prophylaxis prescription guidelines for both inpatients and discharged patients.
Objectives: (1) To assess compliance with Trust’s VTE prevention guidelines and to identify the practical limitations of guidelines.
(2) To promote prevention of hospital acquired venous thromboembolism by emphasizing correct VTE prophylaxis prescription on discharge.
Methodology: This is a retrospective study of total 201 patients, discharged form respiratory wards of Stoke-Mandeville Hospital, between 01.01.21 and 31.03.2021. All patients discharged to homes or nursing homes were included. Patients who were stepped down to other wards or community hospitals and patients who passed away in hospital were excluded.
Results: Up to 87% of the discharged patients were COVID positive who would require VTE prophylaxis to continue at home. This study clearly shows that the more discharge VTE risk assessment is emphasized, the lesser the errors in prophylaxis prescription. In conclusion, Trust’s discharge VTE guideline is a practically useful tool and might play an important role in prevention of hospital acquired thromboembolism, especially in COVID era
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3309.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021